Skip to main content

Table 3 Antimicrobial activity of antimicrobial agents against Acinetobacter baumannii , Haemophilus influenzae and Pseudomonas aeruginosa collected globally between 2004 - 2013

From: Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013

 

MIC 90 (mg/L)

MIC range mg/L

% susceptible

% resistant

Acinetobacter baumannii (n = 16,778)

  

AMK

≥128

≤0.5 – ≥ 128

61.1

32.4

AMC

≥64

≤0.12 – ≥ 64

-

-

AMP

≥64

≤0.5 – ≥ 64

-

-

FEP

≥64

≤0.5 – ≥ 64

44.3

42.9

CAZ

≥64

≤8 – ≥ 64

41.2

52.1

CRO

≥128

≤0.06 – ≥ 128

23.3

54.6

IPM (n = 3,795)

≥32

≤0.06 – ≥ 32

80.0

16.8

LVX

≥16

≤0.008 – ≥ 16

43.0

46.6

MEM (n = 12,983)

≥32

≤0.06 – ≥ 32

54.8

41.1

MIN

8

≤0.5 – ≥ 32

84.5

5.1

TZP

≥256

≤0.06 – ≥ 256

42.9

47.5

TGC

2

≤0.008 – ≥ 32

-

-

Acinetobacter baumannii, MDR (n = 6,743)

  

AMK

≥128

≤0.5 – ≥ 128

18.4

74.1

AMC

≥64

1 – ≥ 64

-

-

AMP

≥64

≤0.5 – ≥ 64

-

-

FEP

≥64

≤0.5 – ≥ 64

5.5

80.1

CAZ

≥64

≤8 – ≥ 64

4.0

90.8

CRO

≥128

≤0.06 – ≥ 128

0.7

94.6

IPM (n = 896)

≥32

0.25 – ≥ 32

30.9

64.6

LVX

≥16

0.03 – ≥ 16

2.4

89.3

MEM (n = 5,847)

≥32

≤0.06 – ≥ 32

11.9

84.0

MIN

16

≤0.5 – ≥ 32

70.3

11.3

TZP

≥256

≤0.06 – ≥ 256

3.0

90.5

TGC

2

≤0.008 – ≥ 32

-

-

Haemophilus influenzae (n = 15,925)

   

AMK

8

≤0.5 – ≥ 128

-

-

AMC

1

≤0.12 – ≥ 64

99.7

0.3

AMP

32

≤0.5 – ≥ 64

78.3

19.3

FEP

≤0.5

≤0.5 – ≥ 64

99.5

-

CRO

≤0.06

≤0.06 – 32

99.9

-

IPM (n = 3,672)

1

≤0.06 – ≥ 32

99.9

-

LVX

0.03

≤0.008 – ≥ 16

99.9

-

MEM (n = 12,253)

0.12

≤0.06 – 2

99.9

-

MIN

1

≤0.5 – ≥ 32

98.6

0.5

TZP

≤0.06

≤0.06 – 64

99.8

0.2

TGC

0.25

≤0.008 – 4

98.9

-

Haemophilus influenzae, BL-pos (n = 3,207)

   

AMK

8

≤0.5 – ≥ 128

-

-

AMC

2

≤0.12 – ≥ 64

98.9

1.1

AMP

≥64

≤0.5 – ≥ 64

0.2

95.2

FEP

≤0.5

≤0.5 – ≥ 64

99.1

-

CRO

≤0.06

≤0.06 – 16

99.9

-

IPM (n = 803)

1

≤0.06 – 4

100

-

LVX

0.03

≤0.008 – ≥ 16

99.8

-

MEM (n = 2,404)

0.12

≤0.06 – 2

99.8

-

MIN

1

≤0.5 – ≥ 32

98.4

0.5

TZP

≤0.06

≤0.06 – 64

99.7

0.3

TGC

0.25

≤0.008 – 1

99.0

-

Pseudomonas aeruginosa (n = 28,413)

   

AMK

16

≤0.5 – ≥ 128

90.2

6.5

AMC

≥64

≤0.12 – ≥ 64

-

-

AMP

≥64

≤0.5 – ≥ 64

-

-

FEP

32

≤0.5 – ≥ 64

74.3

13.5

CAZ

32

≤8 – ≥ 64

74.0

18.1

CRO

≥128

≤0.06 – ≥ 128

-

-

IPM (n = 6,303)

8

≤0.06 – ≥ 32

76.4

17.5

LVX

≥16

≤0.008 – ≥ 16

63.9

29.5

MEM (n = 22,110)

16

≤0.06 – ≥ 32

70.3

22.3

MIN

≥32

≤0.5 – ≥ 32

-

-

TZP

128

≤0.06 – ≥ 256

73.1

15.3

TGC

16

≤0.008 – ≥ 32

-

-

Pseudomonas aeruginosa, MDR (n = 3,496)

   

AMK

≥128

≤0.5 – ≥ 128

46.3

43.5

AMC

≥64

1 – ≥ 64

-

-

AMP

≥64

≤0.5 – ≥ 64

-

-

FEP

≥64

≤0.5 – ≥ 64

8.2

69.0

CAZ

≥64

≤8 – ≥ 64

11.7

77.7

CRO

≥128

2 – ≥ 128

-

-

IPM (n = 557)

≥32

0.5 – ≥ 32

5.9

92.1

LVX

≥16

0.03 – ≥ 16

2.1

96.3

MEM (n = 2,939)

≥32

≤0.06 – ≥ 32

4.9

91.8

MIN

≥32

≤0.5 – ≥ 32

-

-

TZP

≥256

0.25 – ≥ 256

10.9

67.7

TGC

≥32

≤0.008 – ≥ 32

-

-

  1. AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MDR, multidrug-resistant; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin.